{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:42:00Z","timestamp":1770756120171,"version":"3.50.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1702","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara \u2013 Sanofi\/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper.<\/jats:p>","DOI":"10.58347\/tml.2024.1702c","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T16:40:56Z","timestamp":1715791256000},"page":"77-78","source":"Crossref","is-referenced-by-count":2,"title":["Sarilumab (Kevzara) for Polymyalgia Rheumatica"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,5,13]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T16:40:57Z","timestamp":1715791257000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1702c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":0,"journal-issue":{"issue":"1702","published-online":{"date-parts":[[2024,5,13]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1702c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}